Latest News

Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

Ocugen to Participate in Upcoming October Investor and Industry Conferences

EXEED International User Summit: Dual Launch of Design Refresh and Performance Experience Ready to Announce with Confidence?

BeyondSpring Announces FDA Fast Track Designation for Plinabulin in Post-ICI Non-Squamous NSCLC and Strategic Transaction to Advance Global Phase 3 DUBLIN-4 Trial Toward Planned Interim Analysis

Invivyd Announces Positive Topline Results from LIBERTY Phase 3 Study Demonstrating VYD2311 Safety and Tolerability Superior to mRNA-based COVID-19 Vaccine; Announces Regulatory Submission Plans for VYD2311

Insightful Launches MSP Partner Program to Bring Work Intelligence to Managed IT Providers

David's Bridal Names Former Nike & Magnolia Finance Executive Kathy Cherian Chief Financial Officer

PyroGenesis Completes Acquisition of 50% Ownership Interest in HPQ Silica Polvere Inc., Rights-Holder of the Fumed Silica Reactor Technology

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly